Please complete Pre-test

Chapter 1 of 4



Release Date: October 11, 2019
Expiration Date: October 11, 2020

Expected time to complete this activity as designed: 75 minutes
There are no fees for participating in or receiving credit for this online activity.

This activity was previously presented on September 11, 2019 to a live audience during the 2019 SOHO Annual Meeting in Houston, Texas.
Please note: If you attended the live meeting or simulcast viewing, you are ineligible to receive an additional 1.25 contact hours of credit and may not re-submit for credit previously awarded.

Program Overview

The medical landscape of AML is rapidly evolving, as evidenced by updated practice guidelines and the World Health Organization revised diagnostic and prognostic criteria. The challenges facing clinicians in remaining current with the latest evidence in AML represents a major need. As new agents are used in the clinical practice setting, and as emerging therapies reach the likelihood of approval, it will be increasingly important for healthcare practitioners to be aware of the data and engage in education which will allow them to confidently interpret the evidence for real-world practice. This activity will provide clinicians with evidenced-based, and practical expert led instruction on developing optimal treatment strategies for your patients with AML.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with either newly diagnosed or relapsed or refractory acute myeloid leukemia.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Apply updated recommendations for diagnostic and prognostic evaluation of AML in clinical practice, including optimal use of molecular testing
  • Incorporate new and emerging therapies into the treatment paradigm to provide optimal care for patients with newly diagnosed or relapsed/refractory AML
  • Develop individualized treatment plans for patients with AML based on age, risk assessment, and other patient- or disease-related factors
  • Identify active clinical trials in both newly diagnosed and relapsed/refractory AML and incorporate referral to these trials, when appropriate, into treatment plans


Chapter 1 - The Impact of Cytogenetic and Molecular Abnormalities on Patient Management: Diagnostic, Prognostic, and Therapeutic Importance – Naval Daver, MD

Chapter 2 - Current and Emerging Therapies in Newly Diagnosed AML: Adapting Treatment to Meet Needs of the Individual Patient – Eunice S. Wang, MD

Chapter 3 - Optimizing Outcome in Relapsed/Refractory AML: Incorporating New Treatment into Practice – Courtney D. DiNardo, MD, MSCE

Chapter 4 - Evolving Treatment Paradigms in AML: New Data and Clinical Trials That Could Change Clinical Practice – Naval Daver, MD

Instructions for Participation and Credit

This activity is eligible for credit through October 11, 2020. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Naval Daver, MD – Chair
Associate Professor of Medicine
Department of Leukemia 
Division of Cancer Medicine 
The University of Texas MD Anderson Cancer Center
Houston, Texas

Dr. Naval Daver received his medical degree from Grant Medical College and Sir JJ Group of Hospitals, Mumbai, India, followed by a residency and fellowship in hematology-oncology from Baylor College of Medicine in Houston, Texas. He is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center.

A clinical investigator with a focus on molecular and immune therapies in acute myeloid leukemia (AML) and myelofibrosis, Dr. Daver is the co/principal investigator for more than 25 ongoing clinical trials in these diseases. These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune and cytotoxic agents, and identifying and overcoming mechanism of resistance. He is especially interested in developing immune checkpoint- and vaccine-based approaches in AML, myelodysplastic syndromes (MDS), and myelofibrosis, and is conducting a number of these trials. Dr. Daver has published more than 100 peer-reviewed manuscripts. He has also authored numerous abstracts at national and international conferences.

Courtney D. DiNardo, MD, MSCE 
Associate Professor of Medicine 
Department of Leukemia 
Division of Cancer Medicine 
The University of Texas MD Anderson Cancer Center
Houston, Texas

Dr. Courtney DiNardo received her medical degree from the University of Michigan, Ann Arbor. She completed her internal medicine internship and residency, followed by a hematology/oncology fellowship at the University of Pennsylvania. Dr. DiNardo is currently Associate Professor of Medicine in the Department of Leukemia, Division of Cancer Medicine, and Institutional Review Board Vice Chair at The University of Texas MD Anderson Cancer Center in Houston, Texas.

Dr. DiNardo’s clinical research focuses on prognostication and personalized therapeutics in myeloid malignancies. She is primary investigator of multiple novel IDH1/IDH2-targeted therapeutic agents currently in clinical trials and is also involved in the clinical development of venetoclax in combination with hypomethylating agent therapy for the treatment of newly diagnosed elderly AML. Her clinical and research focus on hereditary cancer predisposition syndromes led to development of the MD Anderson Hereditary Hematologic Malignancy Clinic, which provides clinical and research-based evaluation of underlying cancer predispositions and hereditary cancer syndromes in leukemia patients.

Eunice S. Wang, MD
Chief, Clinical Leukemia Service
Professor, Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Dr. Eunice Wang earned her medical degree from the Keck (University of Southern California) School of Medicine. She completed her internship and residency in internal medicine at Yale-New Haven Hospital, followed by clinical and research fellowships in hematology-oncology at Memorial Sloan Kettering Cancer Center in New York. She is Chief of the Leukemia Service and Professor of Oncology in the Department of Medicine at Roswell Park Comprehensive Cancer Center, Buffalo, New York. She is also an Associate Professor in the Department of Medicine, School of Medicine of Biomedical Sciences at the State University of New York at Buffalo (SUNY-UB).

Dr. Wang is a member of several professional organizations including the American Society of Hematology and the American Society of Clinical Oncology. She serves on the National Comprehensive Cancer Network (NCCN) Clinical Practice treatment guidelines panels for acute myeloid and acute lymphocytic leukemia. She is a prior recipient of a NIH Cancer Clinical Investigator Team Leadership Award (CCITLA) and a Mentored Research Scholar award from the American Cancer Society. Dr. Wang has authored/co-authored more than 90 peer-reviewed articles in the field of hematological malignancies. She maintains an active clinical practice with a portfolio of early phase clinical trials in acute leukemias and myeloid malignancies. She also leads a translational laboratory focused on preclinical studies of novel agents targeting the

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.

Supported by educational grants from Agios Pharmaceuticals, Inc., Astex Pharmaceuticals, Jazz Pharmaceuticals, Inc., and Pfizer Inc.

©2019 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-19-023-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
Accreditation Statement: MediCom Worldwide, Inc. is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.25 contact hours. Program Number: 19-023-111


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Naval Daver has received honoraria related to formal advisory activities and as a consultant from AbbVie Inc., Agios, Astellas Pharma US, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo, Inc., ImmunoGen, Inc., Incyte Corporation, Jazz Pharmaceuticals plc, Karyopharm Therapeutics, Otsuka Pharmaceutical Co., Ltd., Novartis AG, Pfizer Inc., and Sunesis. He has received grant support related to research activities from AbbVie, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, GlycoMimetics, Inc., ImmunoGen, Incyte, Karyopharm, Nohla Therapeutics, Novartis, Pfizer, SERVIER, and Sunesis.

Dr. Courtney DiNardo has received honoraria related to formal advisory activities from AbbVie Inc., Agios, Celgene Corporation, Daiichi Sankyo, Inc., Jazz Pharmaceuticals plc, and Syros Pharmaceuticals, Inc., as well as consultant fees from Notable.

Dr. Eunice Wang has received honoraria as a consultant from AbbVie Inc., Agios, Amgen Inc., Arog Pharmaceuticals, Inc., Celyad, Daiichi Sankyo, Inc., ImmunoGen, Inc., Jazz Pharmaceuticals plc, and Pfizer Inc., as well as speakers’ bureau activities from Astellas Pharma US, Inc., Jazz, and Novartis AG. She has received grant support related to research activities from ImmunoGen.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, Joan Meyer, RN, MHA, Executive Director, and Bill Stoff, Director of Operations, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.